These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 28374965)

  • 1. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
    Molino S; Martin MT
    Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection.
    Sikavi C; Najarian L; Saab S
    Dig Dis Sci; 2018 Nov; 63(11):2829-2839. PubMed ID: 30094623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
    Falade-Nwulia O; Suarez-Cuervo C; Nelson DR; Fried MW; Segal JB; Sulkowski MS
    Ann Intern Med; 2017 May; 166(9):637-648. PubMed ID: 28319996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
    Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2015 Aug; 42(3):258-72. PubMed ID: 26014906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.
    Boesecke C; Ingiliz P; Reiberger T; Stellbrink HJ; Bhagani S; Page E; Mauss S; Lutz T; Voigt E; Guiguet M; Valantin MA; Baumgarten A; Nelson M; Vogel M; Rockstroh JK;
    Infection; 2016 Feb; 44(1):93-101. PubMed ID: 26481253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
    Sundaram V; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
    Zanaga LP; Miotto N; Mendes LC; Stucchi RS; Vigani AG
    Braz J Med Biol Res; 2016 Oct; 49(11):e5504. PubMed ID: 27783808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
    Lampejo T; Agarwal K; Carey I
    Dig Liver Dis; 2018 Feb; 50(2):113-123. PubMed ID: 29233687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.